Rubraca rucaparib prescribing information. The prescribing information for olaparib approved in 2014 at 400 mg BID capsules reported several PK param- eter estimates including apparent plasma CL F of 86.
Ndc 0310 0668 Lynparza Olaparib
In vitro olaparib inhibits the efflux transporter P-gp IC50 76µM therefore it cannot be excluded that olaparib may cause clinically relevant drug interactions with substrates of P-gp eg.
Olaparib prescribing information. GBRCAtesting helps inform treatment choices including olaparib LYNPARZA a targeted maintenance therapy for patients with metastatic pancreatic cancer and gBRCAm whose disease has not progressed on 16 weeks of first-lineplatinum-based chemotherapy12 Test your patients with the FDA-approved BRACAnalysis CDxfrom Myriad Genetics. LYNPARZA olaparib prescribing information. 2014 INDICATIONS AND USAGE -----.
Outside of these hours and on holidays an after-hours service is available to assist you with any urgent medical issues. AstraZeneca and Merck Co Inc. Monday to Friday 8 AM to 8 PM ET excluding holidays.
Der Wirkstoff in Lynparza Olaparib hemmt die Wirkung von als humane PolyADP-Ribose-Polymerase PARP bezeichneten Enzymen die im Rahmen der Zellteilung an der Reparatur beschädigter DNA in. Talzenna talazoparib full Prescribing Information. Research Triangle Park NC.
Contraceptives may be reduced if co-administered with olaparib see also sections44and46. Lynparza olaparib regulatory submission granted priority review in US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer news release. LYNPARZA olaparib tablets for oral use Initial US.
LYNPARZA olaparib prescribing information. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and effectively. LYNPARZA olaparib prescribing information.
Advanced ovarian cancer fallopian tube cancer or primary peritoneal cancer with a certain type of inherited germline or acquired somatic abnormal BRCAgene. Golan T Hammel P Reni M et al. Pujade-Lauraine E Ledermann JA Selle F et al.
26 72 123 CYP3A Inducers. See full prescribing information. Avoid concomitant use of strong or moderate CYP3A inducers as decreased efficacy can occur 73 123----- USE IN SPECIFIC POPULATIONS -----.
Lynparza prescribing information. 2018379262 49 5-2 50 5. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.
Rubraca rucaparib package insert. LYNPARZA is a prescription medicine used to treat adults who have. See full prescribing information.
See full prescribing information for LYNPARZA. Published January 13 2020. See full prescribing information.
Talzenna talazoparib prescribing information. Appropriate clinical monitoring is recommended for. Accessed September 17 2020.
Zejula niraparib prescribing information. Simvastatin pravastatin dabigatran digoxin andcolchicine. In normal cells DNA repair during cell division involves BRCA1 and BRCA2 proteins.
HIGHLIGHTS OF PRESCRIBING INFORMATION WARNINGS AND PRECAUTIONS ----- These highlights do not include all the information needed to use LYNPARZA safely and effectively. Olaparib is indicated as maintenance therapy for people with BRCA-mutated high-grade serous epithelial ovarian fallopian tube or primary peritoneal cancer. Zejula niraparib prescribing information.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and effectively. LYNPARZA olaparib prescribing information. N Engl J Med.
N Engl J Med. If you are in the US and would like additional information regarding AstraZeneca drugs please contact the Information Center at AstraZeneca at 800-236-9933 800-236-9933. Weitere Informationen zur Anwendung von Lynparza entnehmen Sie der Packungsbeilage oder wenden Sie sich an Ihren Arzt oder Apotheker.
Moore K Colombo N Scambia G et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LYNPARZA safely and effectively.
It is a poly ADP-ribose polymerase PARP inhibitor.
